Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirikizumab + zotemtegrast
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
zotemtegrast + Omvoh (mirikizumab) is an investigational combination therapy being developed by Eli Lilly and Company for the treatment of moderately to severely active ulcerative colitis. The combination consists of zotemtegrast (formerly MORF-057), an orally bioavailable, small-molecule selective inhibitor of alpha4beta7 integrin, and Omvoh (mirikizumab), an approved humanized IgG4 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). By combining these two distinct mechanisms of action—blocking leukocyte trafficking to the gut via alpha4beta7 integrin inhibition and reducing systemic and local inflammation via IL-23 pathway blockade—the combination aims to deliver enhanced induction efficacy and sustained clinical remission in patients with moderate-to-severe ulcerative colitis who have had inadequate responses to conventional or advanced therapies. The combination is currently being evaluated in the Phase 2 TOPAZ-UC clinical trial.
- Other names
- LY4268989 + mirikizumabLY4268989 + OmvohMORF-057 + mirikizumabMORF-057 + Omvohzotemtegrast + mirikizumabzotemtegrast + Omvoh
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on mirikizumab + zotemtegrast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirikizumab + zotemtegrast.